Rerearch valuation of serum HE4 concerntration in diagnosis of ovarian tumors

Abstract

Ovarian cancer is a gynecologic disease that have a high prevalence and is opten diagnosed at advanced stage. CA125 is a well known marker of ovarian cancer, it has limited sensitivity and specificy for early cancers, many of which are potentially curable. Subjects and Methods: cross-sectional descriptive, 126 patients including the examed and operated patients at the NHOG from 12/2013 to 3/2014. All patients have complete personal information, ultrasound, concentrations of serum HE4 and CA 125 on ARCHITECT test, ARCHITECT HE4 kits, pathological results. Results: The concentration HE4 average of benign group is 49,7 pmol/l in the premenopausal group and 62,4 pmol/l in postmenopausal group (the estimated level is lower than 70 pmol/l and 140 pmol/l ), the acute group and the epithellia carcinoma group has serum HE4 concentrations higher than the benign tumors with statistical significance. With 95CI, HE4 is sensitivive and specificy with 63,6% then 94,7% In pre-menopausal group, the sensitivity and specificity is 66,6% and 96,9% , in postmenopausal group , the sensitivity and specificity is 60,0% and 77,8% . At 95% CI, CA 125 combine with HE4 have sensitivity and specificity 63,6% and 86,7%. According to menstrual period, the sensitivity and specificity in pre-menopausal group is 42,9% and 100%. In postmenopausal patients, the sensitivity and specificity is 60,0% and respectively 85,7%. Conclusions: HE4 is superior to CA125 in discrimination ovarian cancer form begnin ones. The major advantage of HE4 lies in its specificity. However, we see no benefit from combining both markers in clinical practice.